I63.9
Conditions
Interventions
Group 1: Patients presenting with acute stroke syndrome with typical accompanying symptoms (e.g., paresis, cranial nerve deficits, sensory disturbances, dysarthria, aphasia) or acute vestibular syndro
Sponsors
Universitätsklinikum Carl Gustav Carus Dresden
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Group 1/2 [ischemic strokes/ Stroke mimics] - Patients aged 18 years or older - Blood sampling within 24 hours after symptom onset - Acute stroke syndrome with typical accompanying symptoms (e.g., paresis, cranial nerve deficits, sensory disturbances, dysarthria, aphasia), or acute vestibular syndrome (i.e., dizziness, nausea/vomiting, unsteadiness when walking or standing, intolerance to head movement) with suspected stroke. Matched controls: - Age: range +/- 5 years - Same gender as stroke patient - Existing cardiovascular risk factors: at least 2 of the following 6 factors, including arterial hypertension (atrial fibrillation, dyslipoproteinemia, obesity [BMI = 30], type II diabetes mellitus, coronary heart disease/chronic heart failure) - Written informed consent of the participating person or health care proxy
Exclusion criteria
Exclusion criteria: - Patients under the age of 18 years - Missing informed consent - Participants with pre-existing neurological conditions (Parkinson's disease, stroke, dementia, multiple sclerosis, etc.) - Participants with hemorrhagic stroke
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the expression levels of the miRNAsPC-5p-12969, PC-3p-57664, 122-5p, and 211-5p in the plasma of patients with acute ischemic stroke and stroke mimics upon admission to the emergency department (<24 hours after symptom onset), as well as in a matched control cohort, measured by qPCR. | — |
Secondary
| Measure | Time frame |
|---|---|
| - The diagnostic value of the miRNAs: miRNAs PC-5p-12969, PC-3p-57664, 122-5p, and 211-5p in differentiating between acute ischemic strokes, stroke mimics, and matched controls will be investigated. - The influence of clinical variables on the expression levels of the measured miRNAs (age, blood pressure, gender) is being investigated. - Possible association between the expression levels of the measured miRNAs and the functional treatment outcome, using the modified Rankin Scale (mRS) at discharge and 90 +/- 14 days after symptom onset, will be investigated. | — |
Countries
Germany
Contacts
Public ContactJan Emmerich
Universitätsklinikum Carl Gustav Carus Dresden
Outcome results
None listed